Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

An Phase Ib Study of TQB2450 Injection and Anlotinib Hydrochloride Capsules to Treat Triple Negative Breast Cancer (TNBC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03855358
Recruitment Status : Not yet recruiting
First Posted : February 26, 2019
Last Update Posted : February 26, 2019
Sponsor:
Information provided by (Responsible Party):
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of PD-L1 inhibitorin in combination with Anlotinib treatment for patients with triple receptor negative breast cancer treated after failure of standard therapy (including Anthracyclines and/or Taxanes).

Condition or disease Intervention/treatment Phase
Triple Negative Breast Cancer (TNBC) Drug: TQB2450 Injection and Anlotinib Hydrochioride Capsules Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Phase Ib Study of TQB2450 Injection and Anlotinib Hydrochloride Capsules to Treat Triple Negative Breast Cancer (TNBC)
Estimated Study Start Date : March 30, 2019
Estimated Primary Completion Date : June 30, 2020
Estimated Study Completion Date : December 30, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: TQB2450 Injection and Anlotinib Hydrochioride Capsules Drug: TQB2450 Injection and Anlotinib Hydrochioride Capsules
TQB2450 1200mg intravenously (IV) every-3-weeks (Q3W) and Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent




Primary Outcome Measures :
  1. Overall Response Rate(ORR) [ Time Frame: Up to 72 weeks ]
    Overall Response Rate (ORR) defined as the proportion of subjects who achieves a best response of CR or PR, assessed by IRC per the Lugano Classification


Secondary Outcome Measures :
  1. Complete Response (CR) [ Time Frame: Up to 96 weeks ]
    Disappearance of all non-target lesions and normalisation of tumour marker level. All lymph nodes must be non-pathological in size (<10mm short axis).

  2. Overall Survival (OS) [ Time Frame: Up to 96 weeks ]
    From the first dose of TQB2450 to the date of death

  3. Duration of Response (DCR) [ Time Frame: Up to 96 weeks ]
    The percentage of cases with remission (PR+CR) and stable disease (SD) after treatment in the evaluable cases



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Over 18 years old; ECOG physical condition: 0 - 1 points; expected survival time more than 3 months。
  2. Histological or cytological diagnosis of relapsed/metastatic triple receptor negative breast cancer (TNBC).TNBC is defined negatively expression of estrogen(ER), progesterone(PR) and human epidermal receptor-2(HER2).If there is a pathology report of the metastasis, take the histopathology of the metastases as standard. Negative of ER and PR is defined as expression of ER,PR<1% of the tumor cells by immunohistochemistry (IHC). HER2-negative is defined as a score of 0 and 1+ by IHC, or IHC 2+ & fluorescent in situ hybridization (FISH)negative. If the ER2 test result is 0 or 1+ by IHC, FISH detection is optional, but the result must be negative.
  3. Patients had at least one measurable lesion (RECIST 1.1);
  4. Participants has received prior anthracyclines and/or taxanes in first-line therapy. Disease progressed after latest chemotherapy. For adjuvant therapy/neoadjuvant therapy, disease relapse or progression during treatment or within 6 months after treatment is considered as failure of standard therapy.
  5. Subject must have adequate organ functions and meet requirements on laboratory values.:Count of Blood Cells:hemoglobin content(HB)≥80g/L(No blood transfusion was performed within 14 days); absolute neutrophil count (ANC) ≥ 1.5 × 10^9 / L; platelet count (PLT) ≥ 75 × 10^9 / L;; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN,with the exception of patients with hepatic metastases (ALT and AST ≤ 5 × ULN) , Biochemical examination: serum total bilirubin (TBIL) ≤ 1.5 × normal upper limit (ULN), with the exception of patients with Gilbert's syndrome(TBIL≤3×ULN) ; serum creatinine (Cr) ≤ 1.5 × ULN or Creatinine clearance rate>50 μmol/L;Blood coagulation function:Prothrombin time(PT)≤1.5×ULN、International standardized ratio(INR)≤1.5×ULN、Activation partial thrombin time(APTT)≤1.5×ULN、Prothrombin time≤1.5×ULN;Doppler ultrasound evaluation:Left ventricular ejection fraction(LVEF)≥50%×ULN. 6、Women of childbearing potential must have a negative pregnancy test performed within seven days prior to the start of study drug and should agree to use an adequate method of contraception starting with the first dose of study therapy through 8 weeks after the last dose of study therapy.Men enrolled in this trial must use adequate barrier birth control measures during the course of the trial and 8 weeks after the last dose of study therapy;

7、Subject has voluntarily agreed to participate by giving written informed consent.

Exclusion Criteria:

  1. Patients previously treated with vegfr-targeted inhibitor drugs, including anrotinib hydrochloride capsules, or with other pd-1 / pd-l1 / ctla-4 antibodies or other immunotherapy for pd-1 / pd-l1 / ctla-41;
  2. the people who get other monoclonal antibodies have severe hypersensitivity ;
  3. Present or along with other malignancies within 5 years.Except for carcinoma in situ of the cervix, intramucosal carcinoma of the gastrointestinal tract, breast cancer and non-melanoma skin cancer and superficial bladder tumor[Ta,Tis,Ti];
  4. Has any active autoimmune disease or a history of autoimmune disease (as follows, but not limited to: autoimmune hepatitis, interstitial pneumonia, enteritis, vasculitis, nephritis;Subjects with asthma requiring medical intervention with bronchodilators were excluded).However, the following patients were allowed to be enrolled: vitiligo, psoriasis, hair loss without systemic treatment, well-controlled type I diabetes, and hypothyroidism with normal thyroid function after alternative treatment;
  5. Immunosuppressive therapy (>10mg/ day prednisone or other therapeutic hormones) with systemic or absorbable topical hormone therapy is required and replacement therapy for hypothyroidism with normal thyroid function is required within 2 weeks of the first dose;
  6. Patients with multiple factors affecting oral medication (such as inability to swallow, gastrointestinal tract resection, chronic diarrhea, and intestinal obstruction);
  7. Uncontrolled pleural effusion, pericardial effusion or ascites requiring repeated drainage;
  8. Patients with any signs of bleeding or a history of physical illness, regardless of severity;Patients with any bleeding or bleeding event more than CTCAE 3 level within 4 weeks before the first administration;Or the presence of unhealed wounds, fractures, gastric and duodenal active ulcers, ulcerative colitis and other gastrointestinal diseases or the presence of active bleeding in unresected tumors, or other conditions that may cause gastrointestinal bleeding or perforation as determined by the researchers;
  9. Patients have uncontrollable symptoms of brain metastasis, spinal cord compression, cancerous meningitis, or diseases found in CT or MRI during screening within 8 weeks before the first administration;
  10. four weeks before the start of study treatment has been approved or in the research of anti-tumor treatment, including but not limited to, surgery, radiation therapy, chemotherapy, biological target therapy, interventional therapy, immune therapy and anti-tumor Chinese medicine therapy (to be based on the instroction of Chinese traditional medicine, after 2 weeks elution phase can also be set)and so on (note: people who oral targeted drug is less than five drugs half-life;Or oral fluorouracil drugs less than 14 days, mitomycin C and nitroso urea less than 6 weeks;Patients with adverse events (except hair loss) caused by previous treatment did not recover to a level less than or less than CTCAE 1;
  11. Any patient with any serious and / or non controlled disease,including:a)The blood pressure control is not ideal (more than 150 mmHg systolic blood pressure,diastolic blood pressure greater than 90 mmHg) patients;b)Unstable angina, myocardial infarction, grade 2 or more than grade 2 congestive heart failure within 6 months after first administration, or arrhythmia requiring treatment (including QTc more than 480ms);c)The activity or failed to control severe infection (more than II level of AE CTC infection);d)Carriers of hepatitis b virus with a known clinical history of liver disease, including viral hepatitis, must be excluded from active HBV infection, i.e., HBV DNA positive (>1 10^4 copy /mL or >2000IU/mL);Known hepatitis c virus infection (HCV) and HCV RNA positive (>1 x 10^3 copy /mL), or other decompensated liver disease, chronic hepatitis requires antiviral treatment; e)HIV test positive; f)The poor diabetes control (fasting blood glucose (FBG)more than CTCAE 2);
  12. Inoculated with preventive vaccine or attenuated vaccine within 4 weeks after the first dose;
  13. according to the judgment of the researcher, the subject may have other factors that may cause the termination of the study. For example, other serious diseases (including mental diseases) need to be treated together, there are serious laboratory examination abnormalities, accompanied by family or social factors, which may affect the safety of the subject or the collection of data and samples。

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03855358


Contacts
Layout table for location contacts
Contact: Bin He Xu, doctor xubinghe@medmail.com.cn

Sponsors and Collaborators
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Layout table for additonal information
Responsible Party: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
ClinicalTrials.gov Identifier: NCT03855358     History of Changes
Other Study ID Numbers: TQB2450-Ib-07
First Posted: February 26, 2019    Key Record Dates
Last Update Posted: February 26, 2019
Last Verified: February 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Triple Negative Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases